英文标题：Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates: A TriNetX real-world evidence study

中文标题：HER2阳性转移性乳腺癌接受抗体药物偶联物治疗的临床结局中种族与民族差异：基于TriNetX的真实世界证据研究

讲者：Zunairah Shah, MD | Roswell Park Comprehensive Cancer Center

英文标题：Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial

中文标题：瑞波西利联合曲妥珠单抗及内分泌治疗HR+/HER2+晚期乳腺癌患者的IB/II期研究：韩国癌症研究组BR 18-2 MINI试验

讲者：Joohyuk Sohn, MD, PhD | Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine

英文标题：HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial

中文标题：HER2-ADC药物SHR-A1811治疗HER2阳性乳腺癌脑转移患者：REIN试验更新结果

讲者：闫敏，河南省肿瘤医院

英文标题：A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases

中文标题：阿得贝利单抗与贝伐珠单抗联合顺铂/卡铂治疗三阴性乳腺癌脑转移患者的Ⅱ期临床研究

讲者：李婷，复旦大学附属肿瘤医院

英文标题：Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study

中文标题：II期OptiTROP-Breast05研究初步结果：Sacituzumab tirumotecan（芦康沙妥珠单抗，sac-TMT）作为不可切除的局部晚期/转移性三阴性乳腺癌的一线治疗

讲者：殷咏梅，江苏省人民医院

英文标题：Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D)

中文标题：新型KAT6抑制剂PF-07248144在ER+/HER2−转移性乳腺癌患者中的剂量优化：支持III期推荐剂量（RP3D）的I期研究结果

讲者：Patricia LoRusso, PhD, DO, FASCO | Yale School of Medicine

英文标题：Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies (KM-10A/KCSG BR18-13)

中文标题：trastuzumab-pkrb联合gedatolisib治疗接受过2线及以上HER2靶向化疗后进展的HER2阳性转移性乳腺癌患者的II期研究（KM-10A/KCSG BR18-13）

讲者：KyongHwa Park, MD, PhD | Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine

英文标题：Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial

中文标题：前瞻性随机II期试验：评估新辅助奥拉帕利/卡铂（OC）对比多西他赛/表柔比星/环磷酰胺（TAC）治疗具有同源重组缺陷（HRD）的早期三阴性乳腺癌（TNBC）患者的疗效和安全性——ABCSG 45试验的主要结果

讲者：Christian F. Singer, MD, MPH | Department of Obstetrics and Gynecology and Center for Breast Health, Comprehensive Cancer Center, Medical University of Vienna and Austrian Breast and Colorectal Cancer Study Group

英文标题：A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial

中文标题：NeoSTARⅡ期试验研究结果：基于应答指导的新辅助戈沙妥珠单抗/帕博利珠单抗（SG/P）治疗早期三阴性乳腺癌

讲者：Rachel Occhiogrosso Abelman, MD | Massachusetts General Hospital Cancer Center, Harvard Medical School

英文标题：The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer

中文标题：绝经后激素受体阳性早期乳腺癌患者中，含或不含孕酮的内分泌治疗机会窗研究

讲者：Lucy Haggstrom, MD | St Vincent's Hospital Sydney and University of New South Wales

英文标题：Early results of the French multicenter, randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage low risk breast cancer: Analysis of toxicity and cosmetic outcomes

中文标题：法国多中心随机SHARE试验早期结果：比较全乳放疗与加速部分乳腺照射在绝经后早期低风险乳腺癌患者中的毒性及美容结局分析

讲者：Yazid Belkacemi | AP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC)

英文标题：Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial

中文标题：随机、Ⅲ期DAWNA-A研究：Dalpiciclib（达尔西利，Dalp）联合内分泌治疗（ET）作为HR+/HER2-早期乳腺癌（BC）的辅助治疗

讲者：邵志敏，复旦大学附属肿瘤医院

英文标题：Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age

中文标题：NATALEE研究中瑞波西利（RIB）联合非甾体芳香酶抑制剂（NSAI）的疗效和安全性——基于绝经状态和年龄的分析

讲者：Kevin Kalinsky, MD, FASCO, MS | Winship Cancer Institute at Emory University

英文标题：The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer

中文标题：TRADE研究：Ⅱ期试验评估早期HR+/HER2-乳腺癌患者中阿贝西利剂量递增的耐受性

讲者：Erica L. Mayer, MD, FASCO, MPH | Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School